→ Product Design
Target Product Profile and development brief
When a molecule is approved for development, the Target Product Profile and constraints flow into product design as the starting input not as a one-time email.
Portfolio decisions made with the same data that runs your operation
Business Planning is where a generics operation chooses what to develop, what to defer, and what to walk away from. In most organizations this work happens on slide decks that are out of date the day they're presented. Krevyos makes the decisions a property of the same data layer the rest of the operation runs on.
- Domain owner
- Head of Portfolio · VP Strategy · Business Development
- Decision artifacts
- Target Product Profiles · Investment cases · Patent landscape · Pipeline reviews
- Decision cadence
- Stage-gate quarterly · Portfolio annual · Opportunistic ad-hoc
Capabilities
Portfolio scoring and Target Product Profile authoring
Portfolio decisions held as live records with the rationale, assumptions, and competitive context attached not as slide decks that age between reviews.
- Portfolio scoring
- Target Product Profile
Molecule pipeline and patent landscape
Each molecule under consideration carries its patent expiry, exclusivity periods, reference product strategy, and territory plan as a continuous record so a re-evaluation is a query, not a research project.
- Molecule pipeline
- Patent landscape
Market intelligence and competitive filings
Competitor filings, generic entries, and pricing dynamics tracked against the portfolio they affect so a Paragraph IV challenge or an authority decision surfaces against the specific molecules it touches.
- Market intelligence
- Competitive filings
Investment cases and stage-gate decisions
The case for a molecule and the decision to advance, defer, or kill it are linked to the data that drove them so the same exercise next quarter starts from where the last one ended.
- Investment cases
- Stage-gate decisions
Touchpoints
→ Market Access
Territory plan and launch sequencing
Filing territory selection and launch sequencing and the assumptions they rest on: feed the market access work directly, instead of being re-derived later.
→ Regulatory Affairs
Filing strategy and territory routing
The territory strategy that comes out of business planning becomes the input to the regulatory operation, complete with reference product rationale and timing assumptions.
→ Organizations & Resources
Supply strategy and partner identification
Decisions about in-house vs. partnered manufacturing, single vs. dual sourcing, and capacity planning flow into partner qualification work as priorities not as a separate slide deck.
Outcomes
- +2×(indicative)
Portfolio reviews per year, same headcount
Reviews start from the current state of the operation rather than reconstructing it. Cadence rises without a proportional rise in analyst time.
- −40%(indicative)
Time from idea to investment case
The molecule profile, competitive context, and operational implications are queryable. The case becomes assembly, not research.
- 8wk(indicative)
From stage-gate decision to development brief
The decision and the brief share the same data; product design starts from a versioned record, not a translated handoff.
- 100%(indicative)
Decisions traceable to their evidence
Every stage-gate decision carries the data, the assumptions, and the dissenting view that informed it: auditable on demand.
Figures marked indicative are directional benchmarks against comparable generics operations; per-customer numbers replace them in working sessions.
Want to talk?
Same foundation under every service. A conversation usually clarifies where to start.